Mucormycosis Market is anticipated to grow at a CAGR of 7.85% from 2021 to 2027 globally - Axiom MRC
Mucormycosis Market is anticipated to grow at a CAGR of 7.85% from 2021 to 2027 globally - Axiom MRC
Date: December 2021
New York, December 2021: Axiom Market Research & Consulting™ added a report on Mucormycosis Market which includes study on species, diagnosis method, drugs, distribution channel, and geography. The Mucormycosis Market was projected to grow at a CAGR of 7.85% for the forecast period 2021 to 2027. The global market is estimated and forecasted in terms of revenue (USD Million) generated by the Mucormycosis Market.
The factors such as increasing prevalence of the fungal infection, increasing incidences of the immunological diseases, had been responsible for boosting the growth of the mucormycosis market during the forecast period. However the side effects of the drugs had been affecting the growth of the mucormycosis market during the forecast period.
The report analyses the mucormycosis market based on species, diagnosis method, drugs, distribution channel and geography. By species, the mucormycosis market is segmented into rhizopus, cuninghamella, rhizomucor, saksenaea, apophysomyces, lichtheimia, mucor and others. By diagnosis method, the mucormycosis market segmented into magnetic resonance imaging, computed tomography, tissue biopsy and other. By drugs, the mucormycosis market is segmented into amphotericin B, isavuconazole, Posaconazole, voriconazole, flucytosine, fluconazole and other drugs. By distribution channel, the mucormycosis market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Geographically, the mucormycosis market is studied for the regions including North America, Europe, Asia Pacific, and Rest of the World.
Mucor species segment is expected to dominate the mucormycosis market
The factors such as increasing incidences of the immunosuppressant disease, along with the growing and high usage of the steroids in the treatment of the corona virus patients has been boosting the growth of the segment in the mucormycosis market during the forecast period.
The computed tomography diagnosis method segment is estimated to dominate the mucormycosis market
The factors such as increasing prevalence of the fungal diseases, along with the increasing cases of the novel corona virus and the continuously growing technological advancement of the different diseases has been contributing to the growth of the segment in the market during the forecast period.
Amphotericin B drugs segment has been expected to dominate the mucormycosis market
As the amphotericin B drugs have been the only licensed drug for the purpose of antifungal therapy that can possibly be used as the standard care, has been the boosting the growth of the segment during in the mucormycosis market during the forecast period.
Hospital pharmacies distribution channel segment are expected to dominate the mucormycosis market
The factors such as increasing patient football, along with the high rate of the people being admitted in the hospital for the treatment purposes, and the increasing number of the hospitals has been driving the growth of the segment in the mucormycosis market during the forecast period.
North America is estimated to dominate the mucormycosis market
The factors such as high population of the patients, along with the well-developed healthcare infrastructure and the increasing percentage of the diabetes has been responsible for driving the growth of the mucormycosis market in the region during the forecast period.
Key Players
The key players in the mucormycosis market are Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums And Vaccines, Bdr Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited and Tlc Pharma Labs among others.